ABVC BioPharma's Total Assets for the quarter that ended in Dec. 2023 was $14.49 Mil.
During the past 12 months, ABVC BioPharma's average Total Assets Growth Rate was 52.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 25.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 127.50% per year.
During the past 10 years, the average Total Assets Growth Rate was 103.50% per year.
During the past 13 years, ABVC BioPharma's highest 3-Year average Total Assets Growth Rate was 1212.60%. The lowest was -76.50%. And the median was 11.60%.
The historical data trend for ABVC BioPharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
ABVC BioPharma's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABVC BioPharma (NAS:ABVC) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
ABVC BioPharma's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
ABVC BioPharma Total Assets Related Terms
Thank you for viewing the detailed overview of ABVC BioPharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
ABVC BioPharma (ABVC BioPharma) Business Description
ABVC BioPharma Inc is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABVC has been successfully added to your 